STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 October 2003 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
On  6  April  1999  the  Marketing  Authorisation  Holder  (MAH)  submitted  an  application  for  a 
type  II  variation  in  connection  with  an  extension  of  the  indications  to  include  treatment  of 
postmenopausal osteoporosis. At the same time the MAH applied for an update of the Summary 
of  Product  Characteristics  (SPC),  Package  Leaflet  (PL)  and  labelling  to  take  into  account  the 
latest  Quality  Review  of  Documents  Group  recommendations.  The  CPMP  adopted  a  positive 
Opinion  by  a  majority  of  20  out  of  26  votes  with  2  abstentions  on  18  November  1999.  The 
respective Commission decision was issued on 24 March 2000. 
On 16 July 1999 the MAH submitted an application for a type II variation in connection with an 
update the undesirable effects section in the SPC and PL to include very rare cases of rash and 
gastrointestinal  symptoms.  This  followed  the  submission  of  the  first  Periodic  Safety  Update 
Report (PSUR) (covering the period from 09 December 1997 to 08 December 1998) whereby 
the CPMP requested that this section be updated. The ATC code is now been assigned and has 
been  included  at  the  relevant  section  of  the  SPC.  The  CPMP  adopted  a  positive  Opinion  23 
September 1999. The respective Commision Decision was issued on 31 January 2000. 
On  25  April  2000  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of this variation was to add new maximum batch size for the finished product. The procedure 
started on 27 April 2000. The EMEA notified the European Commission on 7 July 2000 that the 
variation  was  accepted  and  did  not  require  any  amendments  to  the  Community  Marketing 
Authorisation. 
On 20 December 2000 the MAH submitted to the EMEA an application for a type I variation in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of  this  variation  was  to  change  the  address  of  the  MAH.  The  procedure  started  on  5  January 
2001. The EMEA notified the European Commission on 25 January 2001 that that the variation 
was accepted. Amendments to the Annexes I, IIIA and IIIB were required and the Commission 
Decision was issued on 6 March 2000. 
On 8 February 2001, the MAH submitted to the EMEA an application for a type II variation in 
accordance  with  Article  6  of  Commission  Regulation  (EC)  542/95  as  amended.  The  scope  of 
this variation was to update the SPC and PL in order to reword and move the contraindication 
related to the use of Evista in patients with signs and symptoms of breast cancer to section 4.4 
of the SPC and to the warning section of the PL. In addition, to add a new warning in section 
4.4  and  the  warning  section  of  the  PL  for  the  use  of  Evista  women  who  have  a  history  of 
marked  elevations  in  triglycerides  in  response  to  oral  oestrogen.  Moreover,  to  add  two 
undesirable effects to section 4.8 of the SPC and undesirable effects section of the PL based on 
the  4th  PSUR  covering  the  period  9  December  1999  to  8  June  2000.  The  CPMP  adopted  a 
positive Opinion for this variation on 27 June 2001. The respective Commission Decision was 
issued on 31 October 2001. 
On  20  April  2001  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of this variation was to change the currently registered specifications for purified water in order 
to  comply  with  the  requirements  of  the  Ph.  Eur.  Monograph  for  purified  water  in  bulk.  The 
procedure started on 27 April 2001. The EMEA notified the European Commission on 18 May 
2001  that  that  the  variation  was  accepted  and  did  not  require  any  amendments  to  the 
Community Marketing Authorisation. 
On  12  June  2001  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of  this  variation  was  a  minor  change  of  manufacturing  process  of  the  active  substance.  The 
procedure started on 19 June 2001. The EMEA notified the European Commission on 13 July 
1/3 
EMEA 2005 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
• 
2001  that  the  variation  was  accepted  and  did  not  require  any  amendments  to  the  Community 
Marketing Authorisation. 
On  11  March  2002  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of this variation was to add a new packaging site and rename an authorised packaging site. The 
procedure  started  on  15  March  2002.  The  EMEA  notified  the  European  Commission  on  15 
April  2002  that  the  variation  was  accepted  and  did  not  require  any  amendments  to  the 
Community Marketing Authorisation. 
On  5  August  2002  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of this variation was to add a manufacturing site. The procedure started on 13 August 2002. The 
EMEA  notified  the  European  Commission  on  11  September  2002  that  the  variation  was 
accepted and did not require any amendments to the Community Marketing Authorisation. 
On 22 August 2002 the MAH submitted to the EMEA an application for a type I variation in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of this variation was a change to the qualitative composition of immediate packaging material. 
The procedure started on 23 August 2002. The EMEA notified the European Commission on 2 
October  2002  that  the  variation  was  accepted  and  did  not  require  any  amendments  to  the 
Community Marketing Authorisation.  
Pursuant to article 61(3) of Council Directive No. 2001/83/EC of 6 November 2001, the MAH 
notified the EMEA on 4 October 2002 of their intention to introduce changes to an aspect of the 
Package Leaflet not connected to the Summary of Product Characteristics. On 11 October 2002, 
the EMEA notified the European Commission that the changes were accepted and the respective 
Commission Decision was issued on 7 November 2002. 
On  12  June  2001  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  II  variation  in 
accordance with Article 6 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of  this  variation  was  a  change  in  the  manufacturing  process  of  the  active  substance.  The 
procedure  started  on  29  June  2001.  The  EMEA  notified  the  European  Commission  on  17 
October  2002  that  the  variation  was  accepted  and  did  not  require  any  amendments  to  the 
Community Marketing Authorisation. 
Pursuant to article 61(3) of Council Directive No. 2001/83/EC of 6 November 2001, the MAH 
notified the EMEA on 21 October 2002 of their intention to introduce changes to an aspect of 
the  PL  not  connected  to  the  SPC.  On  31  October  2002,  the  EMEA  notified  the  European 
Commission that the changes were accepted and the respective Commission Decision issued on 
20 November 2002. 
On 27 September 2002 the MAH submitted to the EMEA an application for a type I variation in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of  this  variation  was  to  add  an  additional  manufacturing  site  for  control  testing  of  bulk 
substance.  The  procedure  started  on  9  October  2002.  The  EMEA  notified  the  European 
Commission  on  9  November  2002  that  the  variation  was  accepted  and  did  not  require  any 
amendments to the Community Marketing Authorisation. 
On 18 December 2002 the MAH submitted to the EMEA an application for a type I variation in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of  this  variation  was  to  include  an  additional  manufacturing  facility  for  packaging  and  batch 
release.  The  procedure  started  on  20  December  2002.  The  EMEA  notified  the  European 
Commission on 14 January 2003 that the variation was accepted and the respective Commission 
Decision was issued on 14 February 2003. 
For the first renewal of Evista, the CPMP was of the opinion that the quality, safety and efficacy 
of  this  medicinal  product  continued  to  be  adequately  and  sufficiently  demonstrated  and 
therefore  considered  that  the  benefit/risk  profile  continued  to  be  favourable  for  the  authorised 
indications  and  issued  on  22  May  2003  a  positive  opinion  for  the  renewal  of  the  Community 
Marketing Authorisation. The respective Commission Decision was issued on 28 July 2003. 
2/3 
EMEA 2005 
 
 
 
 
 
• 
• 
• 
On  30  April  2003  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  I  variation  in 
accordance with Article 4 of Commission Regulation (EC) No. 542/95, as amended. The scope 
of this variation was to replace an excipient with a comparable excipient. The procedure started 
on  5  May  2003.  The  EMEA  notified  the  European  Commission  on  14  May  2003  that  the 
variation  was  accepted  and  did  not  require  any  amendment  to  the  Community  Marketing 
Authorisation. 
On  the  20  December  2002,  the  MAH  submitted  to  the  EMEA  an  application  for  a  type  II 
variation in accordance with Article 6 of Commission Regulation (EC) 542/95 as amended. The 
scope  of  this  variation  was  to  update  the  SPC  sections  4.4,  4.8  and  5.1  on  the  basis  of  new 
clinical  efficacy  and  safety  data  from  the  cumulative  4-year  results  from  the  osteoporosis 
treatment  study.  The  EMEA  notified  the  European  Commission  19  March  2003  that  the 
variation was accepted and the respective Commission Decision was issued on 26 June 2003. 
Pursuant to article 61(3) of Council Directive No. 2001/83/EC of 6 November 2001, the MAH 
notified  the  EMEA  on  26  June  2003  of  a  change  of  the  company  labelling  of  the  logo  and 
branding design (colour, lay out). On 21 July 2003 the EMEA notified the MAH that the change 
was acceptable. 
3/3 
EMEA 2005 
 
 
 
 
 
 
 
